First Reg A+ IPO on Major U.S. Exchange
Last Friday, Myomo, Inc., a commercial stage medical robotics company, announced the completion of its initial public offering (IPO) under SEC Regulation A+, raising $5.0 Million through the sale of 665,498 shares of its common stock at a price to the public of $7.50 per share. Myomo also closed a simultaneous private sale of investment units for total proceeds of $2.9 Million. The combined capital raised is $7.9 Million.
Myomo’s common stock is expected to begin trading on the New York Stock Exchange (“NYSE”) MKT on June 12, 2017, under the symbol “MYO” and is the first Reg A+ IPO to list its securities on a national exchange.
TriPoint Global Equities, LLC, working with its online division BANQ® (www.banq.co), was the lead managing selling agent and bookrunner for the offering. CrowdfundX was the digital marketing agency of record.
“I am very pleased that we have completed a successful IPO and listing on the NYSE MKT, a first under Jumpstart Our Business Startups (JOBS) Act Regulation A+. The proceeds raised provide Myomo with the resources to continue to invest in the MyoPro® product line, as well as increase our sales and marketing efforts to grow our business domestically and internationally,” said Paul R. Gudonis, Chairman and CEO of Myomo.
Learn more HERE.
Pingback: MYO Prices Secondary at Large Discount to Its June Reg A+ IPO | PubCoCEO™